Driving Immunotherapy Innovation through Global Partnerships
Agenus advances its mission through strategic collaborations that expand the reach and impact of our science. While we retain ownership of most programs, select partnerships bring global development expertise, capital, and technology that accelerate discovery, strengthen our pipeline, and improve patient outcomes.
Advancing Global Development through Partnered Directed Programs
Through selective out-licensing agreements, Agenus partners with leading biopharmaceutical companies to advance the development and commercialization of our novel immunotherapy assets. These collaborations extend the reach of our science, enabling broader patient access and continued value creation.
Accelerating Regional Development and Commercial Partnerships
In select markets, Agenus partners with regional leaders to accelerate development, navigate local regulations, and bring our therapies to patients sooner—extending the global reach of our innovation.
Agenus has granted Zydus rights to develop and commercialize its immunotherapy combination, botensilimab and balstilimab (BOT+ BAL), in India and Sri Lanka.
Through this collaboration, Zydus leverages deep regional expertise, infrastructure, and clinical networks to advance local studies and accelerate regulatory approvals—helping deliver next- generation immunotherapies to more patients, faster.
Exploring New Frontiers through Clinical Collaborations
Agenus engages in clinical collaborations that combine our immune-activating agents with innovative therapies from other biopharmaceutical partners. These studies are designed to explore synergistic mechanisms, identify predictive biomarkers, and unlock new therapeutic opportunities across tumor types.
Optimizing Success with Biomarker and AI Partnerships
Agenus and Noetik.ai are working together to use artificial intelligence (AI) to identify which patients are most likely to benefit from the botensilimab and balstilimab (BOT+BAL) immunotherapy combination. This partnership aims to accelerate precision immunotherapy by integrating next-generation AI with real-world tumor biology to enhance trial success and optimize patient outcomes.